Astellas Pharma US will stop distributing Xtandi, a prostate cancer drug that costs about $160,000 each year, to 340B contract pharmacies on Sept. 1, according to a letter obtained by 340B Health. In ...
SAN DIEGO, June 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement as a participating provider with Prime Health Services to provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback